Get the Stockscreener App
14.06
2.63%
0.36
Capricor Therapeutics Inc stock is traded at $14.06, with a volume of 887.52K.
It is up +2.63% in the last 24 hours and up +7.57% over the past month.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
See More
Previous Close:
$13.70
Open:
$14
24h Volume:
887.52K
Relative Volume:
0.63
Market Cap:
$639.31M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-16.94
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
+11.68%
1M Performance:
+7.57%
6M Performance:
+199.79%
1Y Performance:
+248.88%
1-Day Range:
$13.31
$14.11
1-Week Range:
$12.52
$14.11
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
14.06 | 639.31M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 53% CAGR over 5 years, surging 8.8% in the last week alone - Simply Wall St
Krilogy Financial LLC Makes New $287,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Barclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Barclays PLC Buys 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade - MSN
Will Capricor's Deramiocel Make History As The First Approved Treatment For DMD Cardiomyopathy? - RTTNews
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short Interest - MarketBeat
Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail
Certain Common Stock of Capricor Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2025. - Marketscreener.com
Capricor's CAP-1002: A New Hope For Duchenne Muscular Dystrophy? - RTTNews
Application finalized for DMD cell therapy CAP-1002, now deramiocel - Muscular Dystrophy News
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - MSN
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy - Defense World
CAPR Stock Up On Completion Of Rolling Submission Of DMD Drug BLA - Barchart
Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Capricor stock reiterated at Buy at H.C. Wainwright By Investing.com - Investing.com Canada
Capricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s Excited - MSN
Capricor files cell therapy for DMD cardiomyopathy with FDA - pharmaphorum
Capricor completes U.S. marketing submission for lead candidate - MSN
Capricor completes BLA submission for deramiocel - The Pharma Letter
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock - Benzinga
HC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor seeks U.S. marketing nod for DMD drug (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
Capricor completes FDA submission for DMD therapy By Investing.com - Investing.com Canada
Capricor Therapeutics Completes Submission of Biologics - GlobeNewswire
(CAPR) Trading Report - Stock Traders Daily
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Increase in Short Interest - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 26.8% in December - MarketBeat
Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World
State Street Corp Has $7.79 Million Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9%What's Next? - MarketBeat
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Capricor Therapeutics (NASDAQ:CAPR) Trading 5.6% HigherWhat's Next? - MarketBeat
(CAPR) Trading Advice - Stock Traders Daily
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
The Manufacturers Life Insurance Company Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update - MarketBeat
BNP Paribas Financial Markets Buys 15,872 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 5.3%Here's Why - MarketBeat
Capricor Therapeutics (CAPR) Stock Drops Amid Volatile Biotech Sector - GuruFocus.com
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - MarketWatch
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding - Simply Wall St
(CAPR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P. - MarketBeat
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached (NASDAQ:CAPR) - Seeking Alpha
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission - Seeking Alpha
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):